A detailed history of Fairmount Funds Management LLC transactions in Astria Therapeutics, Inc. stock. As of the latest transaction made, Fairmount Funds Management LLC holds 3,554,129 shares of ATXS stock, worth $34 Million. This represents 6.36% of its overall portfolio holdings.

Number of Shares
3,554,129
Previous 3,554,129 -0.0%
Holding current value
$34 Million
Previous $32.3 Million 20.99%
% of portfolio
6.36%
Previous 6.42%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$4.42 - $8.06 $7.31 Million - $13.3 Million
1,652,732 Added 86.92%
3,554,129 $27.3 Million
Q4 2022

Feb 14, 2023

BUY
$7.44 - $14.89 $7.36 Million - $14.7 Million
989,661 Added 108.55%
1,901,397 $28.3 Million
Q3 2021

Nov 15, 2021

BUY
$7.32 - $12.9 $6.67 Million - $11.8 Million
911,736 New
911,736 $8.06 Million

Others Institutions Holding ATXS

About Astria Therapeutics, Inc.


  • Ticker ATXS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 15,178,000
  • Market Cap $145M
  • Description
  • Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...
More about ATXS
Track This Portfolio

Track Fairmount Funds Management LLC Portfolio

Follow Fairmount Funds Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fairmount Funds Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fairmount Funds Management LLC with notifications on news.